Clearmind Medicine Converts $1.75M in Notes at $0.60/Share, Causing Significant Dilution
Summary
Clearmind Medicine converted $1.75 million in promissory notes into common shares at a discounted price of $0.60 per share, leading to significant dilution for existing shareholders.
Key Events
-
Convertible Notes Converted
$1.75 million in convertible promissory notes were converted into common shares.
-
Discounted Conversion Price
The conversion occurred at an agreed price of $0.60 per common share, a discount to the current market price of $0.7682.
-
Significant Share Issuance
Approximately 2.92 million new common shares were issued as a result of the conversion.
-
Floor Price Amendment
The floor price for future conversions under the existing securities purchase agreements was amended to $0.60 per common share.
Analysis
This filing details the conversion of $1.75 million in convertible promissory notes, previously announced on April 14, 2026, into common shares. The conversion occurred at a price of $0.60 per share, representing a substantial discount to the current market price of $0.7682. This conversion results in the issuance of approximately 2.92 million new shares, significantly diluting existing shareholders. The amendment of the floor price to $0.60 per share further solidifies this lower valuation for future conversions under the existing $10 million program.
At the time of this filing, CMND was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.59 to $52.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.